Rosiglitazone Versus Placebo in Chronic Stable Angina

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2006-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We wish to see if the drug rosiglitazone, currently used in the treatment of type 2 diabetes, could be used as a new treatment for angina when compared with placebo in overweight subjects who do not have overt diabetes. The drug will be given for 3 months and the subjects will be have their angina tested, by way of exercise testing, angina quality of life questionnaire and 24-hour ECG monitoring before and after using the drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance

NCT00733174

Impaired Glucose Tolerance

UNKNOWN PHASE4

Rosiglitazone Plaque Study

NCT00123227

Diabetes Mellitus, Type 2 Vascular Diseases Hypertension

UNKNOWN PHASE3

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

NCT02252406

Stable Angina Metabolic Syndrome

COMPLETED PHASE4

Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

NCT00771004

Oxidative Stress Coronary Artery Disease Type 2 Diabetes

COMPLETED PHASE2

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

NCT01763996

Coronary Artery Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Chronic stable angina is a common manifestation of ischaemic heart disease. Current mechanical therapies (percutaneous coronary intervention and coronary artery bypass grafting) and pharmacological therapies (nitrates, calcium channel blockers, betablockers and potassium channel activators) main actions are to treat the end product of ischaemic heart disease on chronic stable angina, i.e. the flow limiting stenosis. We postulate that by treating insulin resistance, an upstream factor in the pathogenesis of ischaemic heart disease, we will improve angina by in turn improving endothelial function. We will attempt to demonstrate this by way of full bruce protocol exercise tolerance test, Seattle Angina Questionnaire and 24 hour ST segment analysis before and after treatment with the insulin sensitiser rosiglitazone for three months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angina Pectoris Metabolic Syndrome X

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rosiglitazone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chronic stable angina - to see if this improves
* Previous positive exercise tolerance test - to ensure that repeating it yields a result
* Disease not suitable for coronary intervention (Coronary artery bypass grafting or angioplasty) - so that best routine care is not withheld
* Do not have overt diabetes - work on this is being undertaken elsewhere
* Body mass index (BMI) greater than 25

Exclusion Criteria

* Diabetes mellitus - see above
* Liver failure (ALT\>70U/l, AST\>80U/l)
* Renal failure (creatinine \> 130mmol/l)
* Cardiac failure - rosiglitazone is contraindicated in those with NYHA 3 and 4 cardiac failure
* Physical disability - if it precludes treadmill testing
* Women of child bearing capacity
* Breast feeding mothers

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No